Software Risk Should Drive Regulation, AAMI, AdvaMed Say
This article was originally published in The Gray Sheet
Executive Summary
Most industry groups weighing in on FDA’s April FDASIA Health IT Report support the agency’s basic ‘hands off’ approach to regulating health management software, but the voluntary standards group AAMI warns that administrative health IT software with incorrect records can lead to poor diagnosis or treatment.
You may also be interested in...
FDA Emphasizes “Deregulatory” Efforts In Mobile Medical Apps Final Guidance
In a long-awaited final guidance, FDA affirmed its plan to practice enforcement discretion for most mobile medical apps, except those applications that present the same risks as conventional FDA-regulated devices. Some digital health stakeholders praised the guidance, while others wished FDA has waited.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.